DIABETES References

1.            Alvarez GG, and Ayas NT. The impact of daily sleep duration on health: a review of the literature. Prog Cardiovasc Nurs 19: 56-59, 2004.

2.         Babu AR, Herdegen J, Fogelfeld L, Shott S, and Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 165: 447-452, 2005.

3.            Brooks B, Cistulli PA, Borkman M, Ross G, McGhee S, Grunstein RR, Sullivan CE, and Yue DK. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 79: 1681-1685, 1994.

4.            Casillas JM, Gremeaux V, Damak S, Feki A, and Perennou D. Exercise training for patients with cardiovascular disease. Ann Readapt Med Phys 50: 403-418, 386-402, 2007.

5.            Chasens ER. Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. Diabetes Educ 33: 475-482, 2007.

6.            Chasens ER, Weaver TE, and Umlauf MG. Insulin resistance and obstructive sleep apnea: is increased sympathetic stimulation the link? Biol Res Nurs 5: 87-96, 2003.

7.            Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Rodeheffer RJ, Cowan LD, and Howard BV. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 141: 439-446, 2001.

8.            Dubnov G, Brzezinski A, and Berry EM. Weight control and the management of obesity after menopause: the role of physical activity. Maturitas 44: 89-101, 2003.

9.            Gagliardi L, and Wittert G. Management of obesity in patients with type 2 diabetes mellitus. Curr Diabetes Rev 3: 95-101, 2007.

10.            Gilbert PA, and Khokhar S. Changing dietary habits of ethnic groups in Europe and implications for health. Nutr Rev 66: 203-215, 2008.

11.            Harsch IA, Schahin SP, Bruckner K, Radespiel-Troger M, Fuchs FS, Hahn EG, Konturek PC, Lohmann T, and Ficker JH. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 71: 252-259, 2004.

12.            Harsch IA, Schahin SP, Radespiel-Troger M, Weintz O, Jahreiss H, Fuchs FS, Wiest GH, Hahn EG, Lohmann T, Konturek PC, and Ficker JH. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 169: 156-162, 2004.

13.            Hassaballa HA, Tulaimat A, Herdegen JJ, and Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 9: 176-180, 2005.

14.            Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115 Suppl 8A: 111S-115S, 2003.

15.            Knutson KL, Spiegel K, Penev P, and Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med Rev 11: 163-178, 2007.

16.       Leslie WS, Hankey CR, and Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 100: 395-404, 2007.

17.            McEwen BS. Sleep deprivation as a neurobiologic and physiologic stressor: Allostasis and allostatic load. Metabolism 55: S20-23, 2006.

18.            McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 Suppl 2: 23-28; discussion 44-25, 2006.

19.            Moulik PK, and Hardy KJ. Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med 20: 290-293, 2003.

20.            Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, Valagussa F, and Marchioli R. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 370: 667-675, 2007.

21.       Ness-Abramof R, and Apovian CM. Drug-induced weight gain. Drugs Today (Barc) 41: 547-555, 2005.

22.       Patel C, Wyne KL, and McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2: 61-66, 2005.

23.       Penev PD. Sleep deprivation and energy metabolism: to sleep, perchance to eat? Curr Opin Endocrinol Diabetes Obes 14: 374-381, 2007.

24.            Piechota G, Malkiewicz J, and Karwat ID. [Obesity as a cause and result of disability]. Przegl Epidemiol 59: 155-161, 2005.

25.       Pijl H, and Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 14: 329-342, 1996.

26.       Pillar G, and Shehadeh N. Abdominal fat and sleep apnea: the chicken or the egg? Diabetes Care 31 Suppl 2: S303-309, 2008.

27.            Punjabi NM, and Polotsky VY. Disorders of glucose metabolism in sleep apnea. J Appl Physiol 99: 1998-2007, 2005.

28.            Saaresranta T, and Polo O. Does leptin link sleep loss and breathing disturbances with major public diseases? Ann Med 36: 172-183, 2004.

29.            Spiegel K, Knutson K, Leproult R, Tasali E, and Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 99: 2008-2019, 2005.

30.            Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 6: 888-894, 2007.

31.       Strohl KP. Diabetes and sleep apnea. Sleep 19: S225-228, 1996.

32.       Strohl KP, Boehm KD, Denko CW, Novak RD, and Decker MJ. Biochemical morbidity in sleep apnea. Ear Nose Throat J 72: 34, 39-41, 1993.

33.       Sulit L, Storfer-Isser A, Kirchner HL, and Redline S. Differences in polysomnography predictors for hypertension and impaired glucose tolerance. Sleep 29: 777-783, 2006.

34.       Toth C, Martinez J, and Zochodne DW. RAGE, diabetes, and the nervous system. Curr Mol Med 7: 766-776, 2007.

35.            Trenell MI, Marshall NS, and Rogers NL. Sleep and metabolic control: waking to a problem? Clin Exp Pharmacol Physiol 34: 1-9, 2007.

36.            Varela-Moreiras G. Controlling obesity: what should be changed? Int J Vitam Nutr Res 76: 262-268, 2006.

37.            Vgontzas AN, Bixler EO, and Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 254: 32-44, 2003.

38.            Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 7: 373-380, 2007.

39.            Wofford MR, and King DS. Relationship between antihypertensive drugs and metabolic syndrome. Metab Syndr Relat Disord 2: 308-314, 2004.